Pfizer Inc. (NYSE:PFE) Receives $33.91 Average PT from Analysts

Pfizer Inc. (NYSE:PFE) has received an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $33.91.

PFE has been the topic of several recent research reports. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Thursday, October 3rd. Finally, Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st.

Pfizer Stock Down 0.3 %

Shares of NYSE:PFE opened at $28.85 on Friday. The firm has a market capitalization of $163.46 billion, a PE ratio of -62.71, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. Pfizer has a 1 year low of $25.20 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm’s 50-day moving average is $29.07 and its two-hundred day moving average is $28.48.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period in the prior year, the firm earned $0.67 EPS. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts predict that Pfizer will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.82%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently -365.21%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Tanager Wealth Management LLP acquired a new stake in shares of Pfizer during the third quarter worth $233,000. International Assets Investment Management LLC purchased a new position in Pfizer during the 3rd quarter worth $146,481,000. Heartland Bank & Trust Co lifted its stake in shares of Pfizer by 8.3% in the 3rd quarter. Heartland Bank & Trust Co now owns 23,068 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 1,777 shares during the period. McAdam LLC boosted its holdings in shares of Pfizer by 13.9% in the third quarter. McAdam LLC now owns 21,533 shares of the biopharmaceutical company’s stock valued at $623,000 after acquiring an additional 2,628 shares in the last quarter. Finally, Guidance Capital Inc. increased its stake in shares of Pfizer by 2.1% during the third quarter. Guidance Capital Inc. now owns 34,886 shares of the biopharmaceutical company’s stock worth $1,019,000 after acquiring an additional 706 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.